Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-78c5997874-4rdpn Total loading time: 0 Render date: 2024-11-05T03:23:21.490Z Has data issue: false hasContentIssue false

2.28 - Valproic Acid

from Mood Stabilizers

Published online by Cambridge University Press:  19 October 2021

Edited by
Michael Cummings  and
Stephen Stahl
Michael Cummings
Affiliation:
University of California, Los Angeles
Stephen Stahl
Affiliation:
University of California, San Diego
Get access

Summary

Typical or first-generation antipsychotic (FGA)

Type
Chapter
Information
Management of Complex Treatment-resistant Psychotic Disorders , pp. 233
Publisher: Cambridge University Press
Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

AbbVie Inc. (2020). Depakote Package Insert. North Chicago, Illinois.Google Scholar
AbbVie Inc. (2020). Depakote Sprinkles Package Insert. North Chicago, Illinois.Google Scholar
AbbVie Inc. (2020). Depakote ER Package Insert. North Chicago, Illinois.Google Scholar
Zydus Pharmaceuticals (USA) Inc. (2020). Divalproex Package Insert. Pennington, New Jersey.Google Scholar
California Department of State Hospitals. (2019). DSH Psychotropic Medication Policy: Valproic Acid/Divalproex Protocol. Sacramento, California.Google Scholar
Lonergan, E. T., Cameron, M., Luxenberg, J. (2004). Valproic acid for agitation in dementia. Cochrane Database Syst Rev, CD003945.Google Scholar
Sykes, L., Wood, E., Kwan, J. (2014). Antiepileptic drugs for the primary and secondary prevention of seizures after stroke. Cochrane Database Syst Rev, CD005398.CrossRefGoogle Scholar
Trinka, E., Hofler, J., Zerbs, A., et al. (2014). Efficacy and safety of intravenous valproate for status epilepticus: a systematic review. CNS Drugs, 28, 623–639.CrossRefGoogle ScholarPubMed
Hayes, J. F., Marston, L., Walters, K., et al. (2016). Adverse renal, endocrine, hepatic, and metabolic events during maintenance mood stabilizer treatment for bipolar disorder: a population-based cohort study. PLoS Med, 13, e1002058.CrossRefGoogle ScholarPubMed
Nevitt, S. J., Sudell, M., Weston, J., et al. (2017). Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. Cochrane Database Syst Rev, 12, CD011412.Google ScholarPubMed
Thomson, S. R., Mamulpet, V., Adiga, S. (2017). Sodium valproate induced alopecia: a case series. J Clin Diagn Res, 11, FR01–FR02.Google ScholarPubMed
Baillon, S. F., Narayana, U., Luxenberg, J. S., et al. (2018). Valproate preparations for agitation in dementia. Cochrane Database Syst Rev, 10, CD003945.Google ScholarPubMed
Graham, R. K., Tavella, G., Parker, G. B. (2018). Is there consensus across international evidence-based guidelines for the psychotropic drug management of bipolar disorder during the perinatal period? J Affect Disord, 228, 216–221.CrossRefGoogle ScholarPubMed
Baudou, E., Benevent, J., Montastruc, J. L., et al. (2019). Adverse effects of treatment with valproic acid during the neonatal period. Neuropediatrics, 50, 31–40.Google ScholarPubMed
Baumgartner, J., Hoeflich, A., Hinterbuchinger, B., et al. (2019). Fulminant onset of valproate-associated hyperammonemic encephalopathy. Am J Psychiatry, 176, 900–903.CrossRefGoogle ScholarPubMed
Jochim, J., Rifkin-Zybutz, R. P., Geddes, J., et al. (2019). Valproate for acute mania. Cochrane Database Syst Rev, 10, CD004052.Google ScholarPubMed
Chakrabarty, T., Keramatian, K., Yatham, L. N. (2020). Treatment of mixed features in bipolar disorder: an updated view. Curr Psychiatry Rep, 22, 15.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Valproic Acid
  • Edited by Michael Cummings, University of California, Los Angeles, Stephen Stahl, University of California, San Diego
  • Book: Management of Complex Treatment-resistant Psychotic Disorders
  • Online publication: 19 October 2021
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Valproic Acid
  • Edited by Michael Cummings, University of California, Los Angeles, Stephen Stahl, University of California, San Diego
  • Book: Management of Complex Treatment-resistant Psychotic Disorders
  • Online publication: 19 October 2021
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Valproic Acid
  • Edited by Michael Cummings, University of California, Los Angeles, Stephen Stahl, University of California, San Diego
  • Book: Management of Complex Treatment-resistant Psychotic Disorders
  • Online publication: 19 October 2021
Available formats
×